NCT05733598 2026-04-02
Study of RP2 in Combination With Second-line Therapy in Patients With Locally Advanced or Metastatic HCC
Replimune, Inc.
Phase 2 Recruiting
Replimune, Inc.
University Hospital, Essen
Genentech, Inc.
Hoffmann-La Roche
European Organisation for Research and Treatment of Cancer - EORTC